The Immunomodulation Lab
Our group investigates the interplay between immune cells and various disease including cancer and inflammation in vivo. Our aim is to understand the mechanism that control immunity and to identify novel targets for cancer immunotherapy.
We focussing on (1) CAR t-cells and (2) neutrophile extracellular traps (NETs).
Pediatric Tumors are particularly immunogenic. We develop and implement cutting-edge CAR t-cell technologies to control or eliminate cancer and to modulate the immune system. In our lab we combine and into novel therapeutic strategies which will ultimately benefit children suffering from cancer or immune disease.
NETs confer protection against infections, but also drive inflammation and immunopathology.
Professor Martin Herrmann is Head of the Immunology Lab at Erlangen University.
Innate Immunity: neutrophils, neutrophil extracellular traps
Professor Patrick Schlegel is Head of Cellular Cancer Therapeutics at the Children's Hospital Westmead, University Sydney
Pediatric solid tumors: next generation CAR-T design